The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis

Respiratory Function Improvement and Lifespan Extension Following Immunotherapy with NP001 Support the Concept That Amyotrophic Lateral Sclerosis (ALS) Is an Immuno-Neurologic Disease

The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral Sclerosis

Macrophage-Targeted Progression of Amyotrophic Lateral Sclerosis (ALS) through Regulation of Microbial Translocation

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses

Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS

NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study